Metabolic / Endocrinology drug pipeline

Diabetes, obesity, thyroid, and broader metabolic-endocrine therapeutics. The fastest-growing area driven by GLP-1 expansion.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. · 209 drugs
2. Sanofi · 65 drugs
3. Eli Lilly and Company · 58 drugs
4. Merck Sharp & Dohme LLC · 46 drugs
5. Pfizer · 43 drugs
6. AstraZeneca · 41 drugs
7. Hanmi Pharmaceutical Company Limited · 38 drugs
8. Novo Nordisk A/S · 36 drugs
9. GlaxoSmithKline · 29 drugs
10. Takeda · 28 drugs

Key drug classes

• SGLT2 inhibitor · 470
• GLP-1 receptor agonist · 122
• DPP-4 inhibitor · 44
• Rapid-acting insulin analog · 37
• Biguanide · 33
• Insulin · 25
• Long-acting basal insulin · 23
• Sulfonylurea · 18
• Glucagon receptor antagonist · 11
• Long-acting basal insulin analog · 11
• Vitamin C [EPC] · 10
• Alpha-glucosidase inhibitor · 10
• Intermediate-acting insulin · 10
• Insulin Analog [EPC] · 8
• Insulin combination therapy · 8

Major diseases in this area

• type 2 diabetes
• obesity

Subscribe

Get metabolic / endocrinology approvals + PDUFA dates in your RSS reader:

• Metabolic / Endocrinology RSS feed · Atom · JSON

Other therapeutic areas